The rise in cancer cases and the growing preference for targeted therapies are accelerating the adoption of immunotherapy, thereby enhancing the role of PET/CT scanners in oncology. These systems facilitate precise evaluation of therapeutic outcomes and disease status. In this context, the PET/CT systems market in Australia is forecast to grow at a compound annual growth rate (CAGR) of 5% between 2025 and 2035, according to GlobalData, a leading intelligence and productivity platform.

GlobalData’s report, “Nuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036”, reveals that Australia PET/CT systems market accounted for 2% share in Asia-Pacific (APAC) market in 2025.

In May 2026, Monash University, in collaboration with The Alfred, announced the launch of the Australian Cancer Research Foundation Centre for Dynamic Immuno-Oncology (CDIO). The initiative is focused on strengthening cancer research, advancing immunotherapy development, and enhancing precision oncology through advanced imaging and clinical trial capabilities. The newly established center will leverage Quadra PET/CT technology alongside immuno-oncology research to accelerate the development of more precise and targeted cancer treatment approaches.

Shamreen Parween, Medical Devices Analyst at GlobalData, comments: “With the increasing emphasis on early-stage cancer identification and precision-driven care, advanced imaging modalities such as Quadra PET/CT are gaining prominence within the oncology ecosystem. These imaging systems enable comprehensive tumor evaluation, facilitate informed clinical decision-making, and optimize therapeutic planning, thereby contributing to improved clinical outcomes and patient survival. Furthermore, sustained investment in diagnostic imaging is expected to strengthen the country’s advanced imaging capabilities within the broader healthcare landscape.”

The partnership aims to advance oncology through research and scientific progress in immunotherapy, while strengthening the role of PET/CT scanners. The initiative is expected to create new opportunities for translational medicine, enhance access to clinical studies, and support the development of improved treatment strategies. Furthermore, these partnerships reinforce Australia’s efforts to expand its biomedical research capabilities and attract further research collaborations and investment opportunities within Australia’s life sciences and healthcare sectors.

Parween concludes: “Continued adoption of advanced imaging technologies is expected to strengthen Australia’s clinical capacity and medical imaging expertise. In the coming years, these advancements may further elevate the country’s role in the APAC healthcare and imaging landscape.”